Navigation Links
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Date:6/13/2008

continue operations as a result, the possible delisting of the Company's common stock from the NASDAQ Capital Market and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended March 31, 2008. In particular, there can be no assurance as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
(Date:8/3/2015)... and MINNEAPOLIS , ... BSX ) has become a significant shareholder and ... representative for Preventice Solutions for cardiology-related diagnostic and ... an important strategic milestone for Preventice Solutions," said ... Strategy Officer, co CEO, Preventice Solutions.  "We are ...
(Date:8/3/2015)... 3, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO ... for the quarter ended June 30, 2015. All comparisons, unless ... Second Quarter 2015 Highlights include: ... $266 million , Total prescriptions dispensed of 234,000, an ... 5.5% , Adjusted EBITDA of $22.7 million, an increase ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... Jennerex,Inc. (San Francisco, CA and Ottawa, Ontario), and ... of the first five patients in a,Phase 2 primary ... JX-594. No significant toxicities were reported, and enrollment of,patients ... The Phase 2 trial involves treatment of patients ...
... Pulmo BioTech Inc. has completed a dual listing. The ... (symbol PBO) in addition to the OTC BB (OTC ... role in the future development and financing of the ... the United States and Canada" - Garry McCann, CEO ...
Cached Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 2Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... analysis for executives and technology professionals in healthcare and technology markets, today announced ... the Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related ...
(Date:8/3/2015)... ... August 04, 2015 , ... Approved ... extensive line up of live courses for the month of August. , Physical ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Putnam counties. As a family owned and operated business, Zeiter’s Septic has ... They are a leader in septic installations because of their continued training and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number ... according to a new publication released today by the AAMC (Association of American Medical ... graduates over the past three decades, the number of black male applicants to medical ...
(Date:8/3/2015)... ... ... According to an opinion piece published July 28 by the Washington Post, the ... weight loss may not be accurate. While this system may work for some people, the ... – based both on the individual and at what point that person is in their ...
Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2
... of Internal Medicine journal, Obese or overweight Chinese individuals ... developing tuberculosis than those at a normal weight. ... undernutrition in both developed and developing countries. In addition, ... a wide range of chronic degenerative conditions, notably, diabetes ...
... University of Washington shows that the work intended for ... economy . ,The research was conducted by a ... Hagopian, professor in the School of Public Health and ... Initiative; and Sally Weatherford, finance and administration director of ...
... guitarist Kevin Eubanks have won the 'World's Sexiest Vegetarians' title at ... new to the title, for she won the tag in 2005 ... for NBC's 'Tonight Show' band leader Eubanks, who bagged votes due ... for the 49-year-old and 'bring honour' to the show. ...
... researchers identify cost-effective treatment for drug-resistant typhoid. Researchers ... may be more effective at treating typhoid fever ... Organisation. ,Enteric fever, of which typhoid fever ... affecting the developing world, where sanitary conditions remain poor. ...
... have found that umbilical cord blood might safely preserve insulin ... ,The study was conducted by a team of ... Florida. ,As part of the study, researchers identified ... their umbilical cord blood at birth, and gave seven patients ...
... study published in the Journal of the National Cancer ... cancers is increasing, but this finding is likely ... Deirdre Cronin-Fenton, Ph.D., of Aarhus University Hospital in Denmark, ... Md., found that the increase in some early stage ...
Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Global Health Enriching the States Economy 2Health News:Gatifloxacin Very Effective for Typhoid Treatment 2
... ring pessary, available in nine ... support, is a very common ... second degree prolapse. The Ring ... used on an accompanying cystocele. ...
The Capio CL Transvaginal Suture Capturing Device allows for a transvaginal suture fixation to Cooper's Ligament for sling procedures...
... SPARC™ Sling System utilizes a suprapubic ... incontinence due to urethral hypermobility and/or ... two curved, narrow-diameter needles and a ... suture that allows for intra-operative tension ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Medicine Products: